Company Overview - SI-BONE, Inc. is a medical device company focused on addressing sacropelvic disorders and is recognized as a global leader in developing innovative surgical technologies [3] - The company pioneered minimally invasive SI joint surgery in 2009 with the introduction of the iFuse Implant System, supporting over 4,500 physicians and facilitating more than 120,000 procedures [3] - SI-BONE has established a strong clinical foundation with over 160 peer-reviewed publications, including two randomized controlled trials, validating the effectiveness of its technologies [3] Upcoming Event - SI-BONE will participate in the 2025 Truist Securities MedTech Conference in Boston, MA, with a fireside chat scheduled for June 17, 2025, at 10:00 a.m. Pacific Time [1] - Investors can register for the conference call and access a live audio webcast on the company's website, which will be archived for at least 90 days post-event [2]

SANTA CLARA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Goldman Sachs 46th Global Healthcare Conference in Miami Beach, FL. Management will be hosting a fireside chat on Tuesday, June 10, 2025, at 8:20 a.m. Pacific Time/11:20 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link ...

Enovis (ENOV) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Kyle Rose - Vice President of Investor RelationsMatthew Trerotola - CEO & ChairmanBen Berry - CFOVijay Kumar - Senior Managing DirectorWilliam Plovanic - Managing Director - Equity ResearchDane Reinhardt - Senior Equity Research AssociateJoseph Conway - Equity Research AssociateRussell Yuen - Equity Research AssociateYoung Li - Senior VP - Equity Research Conference Call Participants Vik Chopra - AnalystRobert Marcus - Analyst ...

Enovis (ENOV) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Hello, everyone, and welcome to the Innovus Corporation Q1 twenty twenty five Results Call. My name is Ezra, and I will be your coordinator today. I will now hand you over to your host, Kyle Rose, Vice President of Investor Relations to begin. Please go ahead. Speaker1 Thank you, Ezra. Good morning, everyone, and thank you for joining us today for our first quarter twenty twenty five results conference call. I'm Kyle Rose, Vice President ...

Company Overview - SI-BONE, Inc. is a medical device company focused on addressing sacropelvic disorders and is recognized as a global leader in developing surgical technologies for these conditions [3] - The company pioneered minimally invasive SI joint surgery in 2009 and has supported over 4,500 physicians in performing more than 120,000 procedures [3] - SI-BONE has established a strong clinical evidence base, including two randomized controlled trials and over 160 peer-reviewed publications [3] Upcoming Event - SI-BONE will participate in the 2025 BofA Securities Healthcare Conference in Las Vegas, with a fireside chat scheduled for May 13, 2025, at 8:40 a.m. Pacific Time [1] - Investors can listen to the conference call by registering online, and a live audio webcast will be available on the company's website [2]

SI-BONE Corporate Overview May 2025 Forward-Looking Statements This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negati ...

SI-BONE (SIBN) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Saqib Iqbal - Senior Director of FP&A and Investor RelationsLaura Francis - Chief Executive OfficerAnshul Maheshwari - Chief Financial OfficerPhillip Dantoin - Assistant Vice PresidentYoung Li - Senior VP - Equity ResearchCaitlin Cronin - Director Conference Call Participants Craig Bijou - Equity Research AnalystDavid Turkaly - Research AnalystDavid Saxon - Senior AnalystRavi Misra - Associate Analyst - Medtech Equity Researc ...

SI-BONE Corporate Overview May 2025 Forward-Looking Statements This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negati ...

Financial Data and Key Metrics Changes - Worldwide revenue for Q1 2025 reached $47.3 million, representing approximately 25% growth compared to the prior year [6][26] - U.S. revenue was $44.8 million, reflecting approximately 27% growth, driven by a 27.3% increase in procedure volume [7][26] - Gross profit was $37.7 million, an increase of $7.8 million or 26.2%, with a gross margin rate of 79.7% [27] - Net loss narrowed to $6.5 million or $0.15 per diluted share, compared to a net loss of $10.9 million or $0.27 per diluted share in the prior year [28] - Positive adjusted EBITDA of approximately $5 million compared to an adjusted EBITDA loss of $4 million in Q1 2024 [29] Business Line Data and Key Metrics Changes - The company experienced broad-based demand for existing technologies and rapid adoption of new solutions launched in 2024 [7][39] - The number of physicians performing procedures using the company's products grew by 27%, with over 1,400 U.S. physicians engaged [19] - The number of four implant Granite cases grew approximately 69% compared to the prior year period [13] Market Data and Key Metrics Changes - The total addressable market has increased to over $3.5 billion, with a cumulative procedure volume growth of 25% over the last three years [9][10] - The company is targeting nearly 100,000 degenerative procedures annually with its Granite product, which became eligible for transitional pass-through payment starting January 1, 2025 [13][14] Company Strategy and Development Direction - The company focuses on innovation, engagement, commercial execution, and operational excellence as key priorities [9] - The strategy includes diversifying the product platform with unique yet complementary technologies to expand the target modalities and physician footprint [9][10] - The company aims to reach 100 territories over the next 12 to 15 months, leveraging a hybrid commercial model combining territory managers and third-party agents [24][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong results over the long term, supported by resilient business trends and favorable reimbursement conditions [8][9] - The updated full-year revenue guidance is between $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [32] - Management noted that the company is well-positioned to achieve free cash flow in 2026, with a focus on maintaining operational discipline [30][32] Other Important Information - The company has a strong pipeline of novel technologies under development, with plans to launch new products over the next 12 to 18 months [16][18] - The company does not anticipate any material impact on gross margins or supply chain from proposed tariffs, as most manufacturing is domestic [30][31] Q&A Session Summary Question: Contribution from new products and channels to growth - Management noted broad-based growth and strong demand for current solutions, with impressive adoption of new products launched in 2024 [39] Question: Drivers of gross margin and future expectations - Management highlighted better-than-expected average selling price (ASP) and efficiency initiatives as key drivers of gross margin improvement [42][44] Question: Long-term growth expectations - Management expressed confidence in sustained growth potential, driven by technology leadership and expanding physician engagement [53][56] Question: Expected cadence of new guidance and sequential growth - Management indicated that while they do not think about the business in quarters, they expect to manage seasonality effectively with new product rollouts [66] Question: Operating expenses guidance - Management explained that elevated R&D investments and higher commissions linked to revenue growth are driving the expected increase in operating expenses [70][72] Question: Update on surgeon base and engagement - Management reported a record increase in the physician base, with broad engagement across various specialties [76][78] Question: Updates on reimbursement proposals - Management provided insights on CMS proposals and the potential for increased reimbursement rates, which could accelerate adoption of products [80][81] Question: Traction and adoption of TNT product - Management noted that TNT is seeing rapid adoption and is expected to benefit from upcoming reimbursement changes [97]

Core Insights - SI-BONE, Inc. reported strong financial results for Q1 2025, with significant revenue growth and improved profitability metrics [3][4][7]. Financial Performance - Worldwide revenue reached $47.3 million, a 24.9% increase from $37.9 million in Q1 2024 [4][9]. - U.S. revenue was $44.8 million, reflecting a 26.6% increase from $35.4 million in the same period last year [4][9]. - Gross profit was $37.7 million, up 26.2% from $29.9 million in Q1 2024, with a gross margin of 79.7%, an improvement of 80 basis points [5][9]. - Operating expenses increased by 7.8% to $45.2 million, driven by higher commercial activity and R&D investments [6][9]. - Operating loss improved by 37.9% to $7.5 million, while net loss decreased by 40.0% to $6.5 million, or $0.15 per diluted share [7][9]. - Adjusted EBITDA was positive at $0.5 million, a significant improvement from an adjusted EBITDA loss of $4.0 million in Q1 2024 [8][9]. Operational Highlights - The company added over 300 active U.S. physicians in the quarter, totaling over 1,400, representing a 27.3% growth [9]. - The strong underlying procedure demand and the rollout of new products contributed to revenue growth [4][9]. Guidance and Outlook - SI-BONE updated its 2025 revenue guidance to a range of $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [10][11]. - The company expects a gross margin of 78% for the full year and anticipates operating expenses to grow at around 10% [10][11].